Skip to main content

abiraterone acetate (Zytiga®)

 

Status: In progress

Treatment of non-metastatic hormone-sensitive prostate cancer at high risk of progression.

Medicine details

Medicine name abiraterone acetate (Zytiga®)
Formulation film coated tablets
Reference number OW20
Indication

Non-metastatic hormone-sensitive prostate cancer at high risk of progression

Company Janssen-Cilag Ltd
BNF chapter Malignant disease & immunosuppression
Submission type One Wales
Status In progress
Date of issue 06/06/2022
Follow AWTTC: